Medicines for Europe | Events | Contacts | Privacy Policy
14th Annual Biosimilar Medicines Group Conference London

THE GATHERING OF THE WORLD'S BIOSIMILARS EXPERTS

28-29
APRIL 2016

Grange Tower Bridge Hotel

2016 CONFERENCE SESSION OUTLINE

FULL PROGRAMME (htm version or pdf version)

REGISTER NOW

HOTEL RESERVATION To check the availability as well as the best rate available please contact Antonia Teixeira at The Grange Tower Bridge Hotel (45 Prescot Street London E1 8GP, UK) P: +44 (0) 207 959 5000 - +44 (0) 207 959 5105 E: towerbridge.groups@grangehotels.com

ADVERTISING, EXHIBITION & SPONSORSHIP OPPORTUNITIES

SEE THE 2015 SLIDESHOW

SHARE THIS PAGE

REPUTATION

Now in its 14th year, the EBG Biosimilars Conference in London has grown steadily and has become the main annual gathering of the world’s biosimilars experts. It is the ‘not to be missed’ biosimilar medicines event if you wish to stay tuned with all market, regulatory and scientific developments. We encourage real debate amongst all stakeholders on the most relevant biosimilar topics, increased communication and interaction with international key regulators and stakeholders, the leading companies in the biosimilar medicines space and hundreds of delegates from all over the world. We also offer great networking opportunities and welcome you to join this rapidly growing international biosimilar experts’ community!

CHAIRPERSONS AND SPEAKERS


2016 KEY THEMES

  • Adopting and rolling-out a multi-stakeholder approach in Europe
  • Reducing the information gap on biosimilar medicines
  • Supporting international regulatory convergence
  • Additional Interactive US Master Class

 

2016 KEY QUESTIONS TO BE ANSWERED

CONTENT DAY I (10.00 - 18.00): MARKET AND MARKET ACCESS

  • EU Success Story: 10 Years of Biosimilar Medicines - The Impact of Biosimilar Competition in European Markets and the Global Outlook More info click here
  • Multi-stakeholder Approach: Key to the Success of Biosimilar MedicinesMore info click here
  • Key Enabler for Uptake: Reducing the Information Gap on Biosimilar Medicines among StakeholdersMore info click here
  • Increasing Access to Biosimilar Medicines in the Hospital Settings around Europe More info click here

CONTENT DAY II (08.30 - 14.00): SCIENCE & REGULATORY

  • Surfing the Wave of International Regulatory Convergence click here
  • Evolving Landscape on Data Requirements to Demonstrate Biosimilarity click here
  • Ask the Regulators click here

WHO SHOULD ATTEND: 

  • National and international Regulatory Agencies
  • Pricing & Reimbursement Authorities
  • Academia
  • Patient Organisations
  • Medical Societies
  • Healthcare Professionals

  • Chief Executives, Executive Directors, Vice Presidents, Heads, Team Leaders and Managers from the Pharmaceutical Industry in the following departments: Commercial Affairs and Strategic Planning, Regulatory Affairs, Drug Safety & Risk Management, Medical Affairs, Legislation and Policy Advice
  • Analysts
  • Consultants and Service Providers
  • And many more…

  • Follow us on #EBGbios16

WHAT PARTICIPANTS SAID OF THE 2015 EDITION:

SEE THE 2015 SPEECHES

  • WELCOME AND KEYNOTE ADDRESS - Sabine Juelicher, Head of D5 - Medicinal Products - Authorisations, European Medicines Agency – DG SANCO, European Commission - click here

  • OPENING KEYNOTE SPEECH - Nick Haggar, 2013-2015 EGA President - click here

  • THE SCIENCE OF EXTRAPOLATION - Martina Weise, MD, PhD, Head, Unit on Diabetes/Cardiology, Federal Institute for Drugs and Medical Devices, Vice-Chair of the EMA Working Party on Similar Biological Medicinal Products (BMWP) of the CHMP and German CHMP Alternate, DE - click here

LIST OF COMPANIES AND ORGANISATIONS PRESENT IN 2015 SEE THE 2015 SLIDESHOW




EBG CONFERENCE 2015

290 REPRESENTATIVES FROM 36 NATIONALITIES

> Number EU MS present: 20
> Number non-EU countries: 16


ABOUT THE BIOSIMILAR MEDICINES GROUP (formerly European Biosimilars Group - EBG)

The Biosimilar Medicines Group (formerly European Biosimilars Group - EBG), a sector group of Medicines for Europe (formerly EGA), represents the leading companies in the biosimilar medicines space. The Biosimilar Medicines Group Members bring competition to the biologicals market, thereby increasing access to highly innovative medical treatments to patients, in Europe and around the world, and supporting the sustainability of the European healthcare systems.


MEDIA PARTNERS AND SPONSORS

CONTACT

Lucia Romagnoli W: www.egaevents.org